天坛生物
(600161)
| 流通市值：364.23亿 | | | 总市值：364.23亿 |
| 流通股本：19.77亿 | | | 总股本：19.77亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,465,071,868.98 | 3,110,392,965.34 | 1,317,766,404.91 | 6,031,865,460.16 |
| 营业收入 | 4,465,071,868.98 | 3,110,392,965.34 | 1,317,766,404.91 | 6,031,865,460.16 |
| 二、营业总成本 | 3,110,810,892.92 | 2,079,476,311.38 | 908,034,937.26 | 3,517,680,781.42 |
| 营业成本 | 2,508,783,669.51 | 1,698,258,337.49 | 713,279,217.18 | 2,732,440,125.66 |
| 税金及附加 | 50,489,295.1 | 31,863,323 | 13,238,297.74 | 60,953,820.06 |
| 销售费用 | 90,082,081.48 | 60,356,476.12 | 34,343,579.04 | 133,389,253.72 |
| 管理费用 | 358,242,659.95 | 232,973,894.35 | 118,340,412.34 | 481,024,899.62 |
| 研发费用 | 103,154,562.83 | 56,936,180.12 | 30,297,221.48 | 142,786,644.46 |
| 财务费用 | 58,624.05 | -911,899.7 | -1,463,790.52 | -32,913,962.1 |
| 其中:利息费用 | 7,571,310.11 | 4,337,436.62 | 2,403,980.7 | 5,120,807.81 |
| 其中:利息收入 | 9,431,006.69 | 6,510,633.51 | 4,450,202.9 | 40,852,679.49 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 25,892,627.46 | 22,432,891.35 | 8,958,360.98 | 63,926,881.42 |
| 资产处置收益 | 204,679.09 | 204,679.09 | 204,679.09 | 37,503.49 |
| 资产减值损失(新) | -7,482,874.86 | -3,801,539.47 | -1,747,267.39 | -53,018,376.3 |
| 信用减值损失(新) | -51,353,589.07 | -33,550,584.65 | -19,718,691.93 | -7,340,604.87 |
| 其他收益 | 32,761,718.17 | 25,759,579.95 | 8,818,518.86 | 39,995,227.79 |
| 四、营业利润 | 1,354,283,536.85 | 1,041,961,680.23 | 406,247,067.26 | 2,557,785,310.27 |
| 加:营业外收入 | 1,984,135.74 | 1,845,000.68 | 292,883.21 | 1,161,597.68 |
| 减:营业外支出 | 8,870,391.23 | 5,436,525.64 | 261,459.89 | 11,729,405.16 |
| 五、利润总额 | 1,347,397,281.36 | 1,038,370,155.27 | 406,278,490.58 | 2,547,217,502.79 |
| 减:所得税费用 | 226,940,153.37 | 172,570,069.13 | 68,995,470.46 | 434,952,986.44 |
| 六、净利润 | 1,120,457,127.99 | 865,800,086.14 | 337,283,020.12 | 2,112,264,516.35 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,120,457,127.99 | 865,800,086.14 | 337,283,020.12 | 2,112,264,516.35 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 818,686,340.45 | 632,562,146.1 | 244,145,675.45 | 1,549,164,832.24 |
| 少数股东损益 | 301,770,787.54 | 233,237,940.04 | 93,137,344.67 | 563,099,684.11 |
| 扣除非经常损益后的净利润 | 802,892,461.06 | 618,015,305.4 | 239,155,852.86 | 1,518,650,457.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.41 | 0.32 | 0.12 | 0.78 |
| (二)稀释每股收益 | 0.41 | 0.32 | 0.12 | 0.78 |
| 八、其他综合收益 | - | - | - | 19,095,716.14 |
| 归属于母公司股东的其他综合收益 | - | - | - | 14,131,784.73 |
| 九、综合收益总额 | 1,120,457,127.99 | 865,800,086.14 | 337,283,020.12 | 2,131,360,232.49 |
| 归属于母公司股东的综合收益总额 | 818,686,340.45 | 632,562,146.1 | 244,145,675.45 | 1,563,296,616.97 |
| 归属于少数股东的综合收益总额 | 301,770,787.54 | 233,237,940.04 | 93,137,344.67 | 568,063,615.52 |
| 公告日期 | 2025-10-25 | 2025-08-22 | 2025-04-26 | 2025-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |